Targeted-release budesonide for patients with IgA nephropathy.

Abstract

Commentary on: Lafayette R, Kristensen J, Stone A, et al Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet 2023;402:859-70.Series co-ordinator: Dr Teck Khong, DTB Associate Editor, Clinical Pharmacology, St George's, University of London, UK.